专利检索_ ..双子叶植物纲专利检索_ ..双子叶植物纲专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
1	Transcutaneous application of marijuana	US73111	1998-05-05	US06132762A	2000-10-17	Walter Cristobal
A transcutaneous therapeutic formulation comprising marijuana and a carrier for the treatment of pain, inflammation, arthritis and related disorders in humans and animals.
2	Composition and topical formulation of antiandrogens of natural (plant) origin	US817146	1997-06-19	US6113926A	2000-09-05	Jose Cabo Soler; Juan Bautista Peris Gisbert
A composition consisting essentially of a plant extract rich in antiandrogenic sterols from dwarfpalms, African plums, willow herbs, nettle herbs, or hops. The composition can be combined with an acceptable carrier agent to form a variety of topical formulations for cosmetic and pharmaceutical purposes.
3	Methods and materials for treating depression and mood disorder	US368789	1999-08-05	US6068846A	2000-05-30	Suk H. Cho; Lynn Perkes
The present invention provides methods and materials for the treatment of depression or mood disorder. Specifically, the invention involves the use of 5-HTP and an extract to treat depression or mood disorders when administered orally. In addition, the invention provides less expensive, naturally derived dietary supplements to treat mild to moderate depression or mood disorder.
4	Phytoestrogen supplements prepared from pomegranate material including pomegranate seeds	US285703	1999-04-05	US6060063A	2000-05-09	Ephraim Philip Lansky
A phytoestrogen supplement and methods of preparation are described. The basis of the oral phytoestrogen supplement was a preparation of the pomegranate material, preferably pomegranate seeds, which were contacted with an appropriate solvent as described below, preferably including water and ethanol. Preferably, the supplement also included an herbal mixture, including schizandra berries and Chinese asparagus root, and most preferably including Chinese licorice root and Chinese angelica root. The phytoestrogen supplement can also be prepared from pomegranate material alone without the addition of other herbals, which involves fermenting the pomegranate material including the pomegranate seeds. The basis of topical phytoestrogen supplements was a mixture of a preparation of the pomegranate material, preferably pomegranate seeds, which were pressed as described below to produce pomegranate oil, and of the coconut milk. Preferably, the supplements also included schizandra berries and Chinese asparagus root.
5	Herbal composition for diabetes and method of treatment	US95306	1998-06-10	US6042834A	2000-03-28	Mohamed Wasif Baraka
An herbal composition for the treatment of diabetes, comprising 15 percent by weight of dried, powdered seeds of Trigonella foenum-graecum; 23 percent by weight of dried, powdered seeds of Nigella sativa; 10 percent by weight of dried, powdered leaves of Origanum vulgare; 10 percent by weight of dried, powdered sap of Rosmarinus officinalis; 15 percent by weight of dried, powdered beans of Lupinus termis; 12 percent by weight of dried, powdered black leaves of Lawsonia inermis; and 15 percent by weight of dried, powdered seeds of Foeniculum vulgare. The herbal composition may be administered in non-encapsulated powder form or in capsule form. A method of treatment for diabetes using the herbal composition comprises monitoring a diabetic patient's blood sugar level; administering to the patient the herbal composition in an amount of about 9 g per day for at least about 60 days until such date as the patient's blood sugar level achieves and maintains normalcy; administering to the patient the herbal composition in the amount of about 6 g per day for about another 7 days; administering to a patient the herbal composition in the amount of about 3 g per day for about another 14 days; and discontinuing administration, or, alternatively, continuing administration of the herbal composition as necessary for the patient at about less than or equal to 3 g per day of the herbal composition.
6	Nontoxic extract of Larrea tridentata and method of making the same	US329359	1999-06-10	US6039955A	2000-03-21	Robert A. Sinnott; W. Dennis Clark; Kenneth Frank DeBoer
A nontoxic, therapeutic agent having pharmacological activity comprising concentrated extract of Larrea tridentata plant material and ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol or vitamin E is made by a process in which the plant material is extracted using an organic solvent, preferably acetone, and is then saturated with one of the listed reducing agents acid to reduce the toxic NDGA quinone, which naturally occurs in the plant material, to NDGA itself. Additional amounts of ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol, or vitamin E may be added to the extract to inhibit the natural oxidation of the NDGA into the toxic NDGA quinone in vivo, or during processing or storage. The resulting extract is usefull in the treatment of viral diseases caused by viruses from the Herpesviridae family or viruses which require the Sp1 class of proteins to initiate viral replications. The resulting compound can also be used as an anti-inflammatory when the inflammatory diseases are mediated by the effects of leukotrienes. The listed reducing agents can also be used to stabilize NDGA as a therapeutic agent or a food additive.
7	Herbal extract composition and method with immune-boosting capability	US102355	1998-06-23	US06030622A	2000-02-29	Ahmad Abdallah Shehadeh
An herbal extract composition comprising extract of ARUM, extract of POMEGRANATE, extract of TEA and extract of HIBISCUS. The herbal extract composition of the invention demonstrates in vitro stimulation of lymphocyte transformation and cytokine production, and in vitro inhibition of gp120 binding, and provides a potential candidate for therapies and treatments for immune disorders and HIV infection.
8	Process for the removal of undesired lipophilic contaminations and/or residues, which are contained in beverages or in vegetable preparations	US208004	1998-12-09	US6024998A	2000-02-15	Mathias-Heinrich Kreuter; Rudolf Steiner
A process for the removal of undesired lipophilic contaminations and/or residues, which are contained in beverages or in vegetable preparations. The process comprises a first step in which a beverage or vegetable preparation is mixed with a lipophilic phase such that the contaminations and/or residues to be removed are dissolved in the lipophilic phase and are concentrated therein nearly quantitatively. In a second step, the lipophilic phase, which contains the contaminations and/or residues, is separated from the beverage or vegetable preparation. Finally, the purified beverage or vegetable preparation is obtained.
9	Topical salve	US210003	1998-12-11	US6017551A	2000-01-25	George E. Riley
A salve or skin care product for treating discomfort due to burned, inflamed or irritated skin includes a mixture of naturally occurring neutral organic glyceryl esters of fatty acids, such as lard, and small particles of the bark of an Alder tree. The small particles are obtained by pulverized, milling or the like.
10	Cell proliferator and applications thereof	US947164	1997-10-08	US6010701A	2000-01-04	Yumiko Matsukura; Kazuhiko Tokoro
A cell proliferator comprising as an active ingredient a distilled residue of an extract obtained by extracting one or more specific plants as raw materials of spicery with one or more solvents selected from the group consisting of water, lower alcohols, polyol type organic solvents, petroleum ether and hexane; a spicery composition comprising the cell proliferator; an external agent for skin comprising the cell proliferator; and a bathing agent comprising the cell proliferator.
11	Natural preparation for treatment of male pattern hair loss	US303675	1999-05-03	US5972345A	1999-10-26	Stephen Chizick; Rico Delorscio
The present invention is directed to a natural formulation for treatment of male pattern hair loss. The formulation contains a combination of Saw Palmetto extract, African Pygeum extract, stinging nettle extract, and optionally zinc, vitamin B6 and green tea extract. The various extracts are prepared according to the traditional procedures, then combined in a suitable formulation for administration to the patient for treatment of the male pattern hair loss.
12	Mixtures derived from grains of eugenia jambolana lamarck, preparation and use of said mixtures and some of their constituents as medicaments	US117843	1998-08-06	US5972342A	1999-10-26	Albert Rakoto Ratsimamanga; Suzanne Rakoto Ratsimamanga; Philippe Rasoanaivo; Jean Leboul; Jean Provost; Daniel Reisdorf
The present invention relates to mixtures which can be isolated from grains of Eugenis Jambolana Lamarck, the preparation of such mixtures, the medicaments containing said mixtures or constituents of said mixtures, and the use of these mixtures and constituents for the preparation of a medicament.
13	Compositions and methods for weight reduction	US206081	1998-12-04	US5945107A	1999-08-31	Lasse Lief Hessel; Jorgen Scherning Lundsgaard
Compositions containing a combination of selected herbal plant extracts that inhibit gastric emptying time and increase metabolic rate are provided which are useful in reducing weight in patients.
14	Montoxic extract of Larrea tridentata and method of making the same	US152054	1998-09-11	US5945106A	1999-08-31	Robert A. Sinnott
A nontoxic, therapeutic agent having pharmacological activity comprising concentrated extract of Larrea tridentate plant material and ascorbic acid is made by a process in which the plant material is extracted using an organic solvent, and is then saturated with ascorbic acid to reduce the toxic NDGA quinone, which naturally occurs in the plant material, to NDGA itself. Additional amounts of ascorbic acid are added to the extract to inhibit the natural oxidation of the NDGA into the toxic NDGA quinone in vivo, or during processing or storage. The resulting extract is useful in the treatment of viral diseases caused by viruses from the Herpesviridae family or viruses which require the Sp1 class of proteins to initiate viral replications. The resulting compound can also be used as an anti-inflammatory when the inflammatory diseases are mediated by the effects of leukotrienes. The listed reducing agents can also be used to stabilize NDGA as a therapeutic agent or a food additive.
15	Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same	US241692	1994-05-12	US5888984A	1999-03-30	Harold G. Brown
The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates and natural or synthetic essential oils can work effectively as a topical pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion cascade.
16	Methods for inhibiting topoisomerase using procyanidin oligomers	US834637	1997-04-14	US5877206A	1999-03-02	Leo J. Romanczyk, Jr.; John F. Hammerstone, Jr.; Margaret M. Buck
Disclosed and claimed are cocoa extracts such as polyphenols or procyanidins, methods for preparing such extracts, as well as uses for them, especially as antineoplastic agents and antioxidants. Disclosed and claimed are antineoplastic compositions containing cocoa polyphenols or procyanidins and methods for treating patients employing the compositions. Additionally disclosed and claimed is a kit for treating a patient in need of treatment with an antineoplastic agent containing cocoa polyphenols or procyanidins as well as a lyophilized antineoplastic composition containing cocoa polyphenols or procyanidins. Further, disclosed and claimed is the use of the invention in antioxidant, preservative and topiosomerase-inhibiting compositions and methods.
17	Method and composition for selectively inhibiting melanoma	US858011	1997-05-16	US5869535A	1999-02-09	John M. Pezzuto; Tapas K. DasGupta; Darrick S. H. L. Kim
A composition and method of preventing or inhibiting tumor growth, and of treating malignant melanoma, without toxic side effects are disclosed. Betulinic acid or a betulinic acid derivative is the active compound of the composition, which is topically applied to the situs of tumor.
18	Non-irritating capsaicin formulations and applicators therefor	US106834	1998-06-30	US5869533A	1999-02-09	Stephen D. Holt
A delivery system for applying a formula containing capsaicin together with another ingredient to neutralize the discomfort resulting from the application of capsaicin to the skin which involves the topical application of capsaicin by use of patches, use of second skin, use of sprays and includes a unique method for applying the formulation using laser on the epidermis.
19	Skin treatment composition	US863733	1997-05-27	US5869062A	1999-02-09	Benjamin Oliver
An improved skin treatment composition is provided. The composition comprises calamine in an amount between about 8% and 20%, an antioxidant in an amount between about 0.05 and 3 weight percent; and an herbal anti-bacterial substance in an amount between about 0.25 and 4 weight percent. These ingredients are combined with a base, preferably comprised of water and glycerin, in order to prepare the inventive composition. The base will generally comprise from between 25% and 60% by weight of the overall composition.
20	Portulaca oleracea and tumor cell growth	US759403	1996-12-04	US5869060A	1999-02-09	Ji-Won Yoon; Seung Shi Ham; Hee Sook Jun
Portulaca oleracea has been used throughout history for many different medicinal purposes. This invention is directed to the novel use of P. oleracea for the treatment of cancer. More specifically it is disclosed that P. oleracea has a specific and distinct effect on the inhibition and/or suppression of gastric tumor cell growth in vitro and in vivo. An aqueous extract of P. oleracea showed a tumoricidal activity against KATO III (human gastric carcinoma cell line) and COLO 320 HSR cells (human colon adenoma cell line) in a dose-dependent and time-dependent manner, but not against the non-tumorous cell lines, L929 (murine lung connective tissue) and W138 (human lung diploid cell) cells. Subcutaneous injection of six week old CD1 nude mice with COLO 320 HSR cells and subsequently Portulaca oleracea extract showed a clear inhibition of tumor growth as compared to the control nude mice which received only COLO 320 HSR cells.

1 2 3 4 5 6 7 8 9 10

该功能需要专业版企业版VIP权限，您可以：